<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02725658</url>
  </required_header>
  <id_info>
    <org_study_id>NIH/LAMMP-2015-2355</org_study_id>
    <nct_id>NCT02725658</nct_id>
  </id_info>
  <brief_title>Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI</brief_title>
  <official_title>Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beckman Laser Institute and Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beckman Laser Institute University of California Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to help us learn if an experimental imaging device
      called Diffuse Optical Spectroscopic Imaging (DOSI) can monitor tumor shrinkage during
      chemotherapy treatment and can predict if the tumor will respond to chemotherapy before the
      end of the treatment. This study will also help us understand the biological reason for how
      DOSI works.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is considerable interest in developing imaging protocols to monitor and predict breast
      cancer response to neoadjuvant chemotherapy (NAC), which is chemotherapy given before
      surgical removal of the tumor, both prior to and as early as possible during the course of
      treatment. The efficacy and practicality of conventional imaging approaches in the NAC
      setting varies and identifies the need for alternate functional imaging strategies. Diffuse
      optical spectroscopic imaging (DOSI) is an experimental imaging method that allows patients
      to be followed before and during treatment with a cost-effective, bedside, handheld scanning
      probe. DOSI is a non-invasive technology developed at the University of California, Irvine
      Beckman Laser Institute. Studies will be performed at seven clinical sites on approximately
      200 suspected breast cancer patients, of which 150 are expected to undergo neoadjuvant
      chemotherapy (NAC).

      As a primary aim, the investigators will evaluate whether DOSI can predict NAC pathologic
      complete response (pCR), which is defined as no tumor cell left in the resected tissue at
      surgery) by the mid-point of the therapy regimen. As non-invasive DOSI is obtained rapidly
      with no risk/discomfort, this experimental imaging modality could be used as an indicator of
      pathologic response which has been an established indicator of long-term survival. The
      investigators long-term goal is to provide oncologists with a relatively simple, risk-free
      bedside tool that can be used to help inform medical decisions on chemotherapy regimen,
      duration, and timing of surgery, thereby maximizing therapeutic response and minimizing
      unnecessary toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of oxy-hemoglobin (HbO2), in blood.</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of deoxy-hemoglobin (HHb) in blood.</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of total hemoglobin in blood.</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Water content of tissue (%)</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bulk lipid in tissue (%)</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Tumor</condition>
  <arm_group>
    <arm_group_label>DOSI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DOSI</intervention_name>
    <description>Breast tissue properties scanning</description>
    <arm_group_label>DOSI</arm_group_label>
    <other_name>Diffuse Optical Spectroscopy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females between the ages of 21 and 80. Specific to Study part #1

          -  Diagnosed with a Breast Imaging-Reporting and Data System score of 4 or higher breast
             abnormality greater than 1cm in size Specific to Study part #2

          -  Enrolled in study part #1

          -  Diagnosed with histologically-proven invasive breast cancer

          -  Prescribed neoadjuvant chemotherapy for breast cancer

        Exclusion Criteria:

          -  Pregnant

          -  Unable to give written, informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce J Tromberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beckman Laser Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ata Sharif, MD, MBA</last_name>
    <phone>949-824-9265</phone>
    <email>jehren@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas O'Salivan, PhD</last_name>
    <phone>9498248838</phone>
    <email>tosulliv@uci.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pacific Breast Care Clinic</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92627</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ata Sharif, MD, MBA</last_name>
      <phone>949-824-9265</phone>
      <email>sharifs@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Freddie Combs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice Police, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beckman Laser Institute University of California Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ata Sharif, MD, MBA</last_name>
      <phone>949-824-9265</phone>
      <email>sharifs@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Bruce J Tromberg, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas O'Salivan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Durkin, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ylenia Santoro, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anais Leproux, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Hill, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Ehren, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ata Sharif, MD, MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ata Sharif, MD, MBA</last_name>
      <phone>949-824-9265</phone>
      <email>sharifs@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Thomas O'Salivan, PhD</last_name>
      <phone>9498248838</phone>
    </contact_backup>
    <investigator>
      <last_name>Karen T Lane, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Mehta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chaitali Nangia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Carroll, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erin Lin, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxana Dhada, SRA</last_name>
      <phone>415-885-7506</phone>
      <email>Roxana.Dhada@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>David McCoy</last_name>
      <phone>(415) 206-2647</phone>
      <email>David.Mccoy@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nola Hylton, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Greenwood, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bonnie Joe, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Beckman Laser Institute and Medical Center</investigator_full_name>
    <investigator_title>Bruce Tromberg, PhD, Director Beckman Laser Institute and Medical Clinic, Professor, Departments of Biomedical Engineering and Surgery</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant Therapy</keyword>
  <keyword>Diffuse Optical Spectroscopic Imaging</keyword>
  <keyword>DOSI</keyword>
  <keyword>Neoadjuvant Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

